Girish Mahajan (Editor)

Amitifadine

Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Covid-19
CAS Number  410074-73-6
ChemSpider  9833390
KEGG  D10088
PubChem CID  11658655
UNII  GE0J375F8F
Molar mass  228.118 g/mol
Amitifadine wwwneurovancecomwpcontentuploads201507amit
Legal status  US: Investigational New Drug

Amitifadine (am-i-TIF-a-deen) (DOV-21,947 or EB-1010) is an antidepressant drug being developed by Euthymics Bioscience Inc. It is a so-called triple reuptake inhibitor (TRI) or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).

It is the (+)-enantiomer of DOV-216,303, and its (−)-enantiomer is DOV-102,677. Ki values for SERT, NET, and DAT are 99 nM, 262 nM, and 213 nM. The IC50 values for serotonin, norepinephrine and dopamine uptake are 12, 23 and 96 nM, respectively

Amitifadine reduces the duration of immobility in the forced swim test in rats with an oral minimum effective dose (MED) of 5 mg/kg. This antidepressant-like effect manifests in the absence of significant increases in motor activity at doses of up to 20 mg/kg. Amitifadine also produces a dose-dependent reduction in immobility in the tail suspension test, with an oral MED of 5 mg/kg. In microdialysis studies, amitifadine increased extracellular levels of serotonin, norepinephrine and dopamine in brain regions and did not induce hyperactivity in rats. Results in a small clinical trial indicated that amitifadine had statistically significant antidepressant effects and was well tolerated.

References

Amitifadine Wikipedia


Similar Topics
The Return of the Sister Street Fighter
Yves Buysse
Tracey Mosley
Topics
 
B
i
Link
H2
L